Skip to main content
Clinical Trials/NCT03907839
NCT03907839
Completed
Not Applicable

Effects of Cognitive Training Combined With Pulmonary Rehabilitation on Exercise Tolerance and Cognitive Functions in COPD Patients: a Randomized Controlled Trial

Faculty of Medicine, Sousse0 sites60 target enrollmentDecember 15, 2016
ConditionsCOPD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COPD
Sponsor
Faculty of Medicine, Sousse
Enrollment
60
Primary Endpoint
6 minute walk test
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

This study was to examine the effect of endurance training combined with cognitive training in patients with COPD. The intervention group underwent Cognitive Training added to Endurance Training and the control group underwent only Endurance Training.

Detailed Description

Pulmonary rehabilitation is an essential part of the management of COPD. Although various methods and therapies of PR have been used in COPD patients. Furthermore, the Cognitive Training has been performed people with mild cognitive impairments. Therefore, the combination of endurance training and cognitive tarining could be another alternative to improve the exercise tolerance and cognitive function in patients with COPD. It may also be useful for clinicians interested in designing new rehabilitation therapies. The aim of the study was to analyze the effect of CT combined with ET on exercise tolerance and cognitive functions in COPD patient.

Registry
clinicaltrials.gov
Start Date
December 15, 2016
End Date
March 15, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Factorial
Sex
Male

Investigators

Sponsor
Faculty of Medicine, Sousse
Responsible Party
Principal Investigator
Principal Investigator

Imen Sanaa

PhD

Faculty of Medicine, Sousse

Eligibility Criteria

Inclusion Criteria

  • clinically stable COPD diagnosed by pulmonary function testing (2) absence of heart diseases, severe psychiatric, neurologic or musculoskeletal conditions and /or instable cardiovascular diseases. (3) Absence of medication influencing cognition (4) without history of brain injury, history of stroke or history of alcoholism.

Exclusion Criteria

  • smoking COPD
  • heart diseases
  • instable cardiovascular diseases

Outcomes

Primary Outcomes

6 minute walk test

Time Frame: 1 day

The patients are instructed to cover the maximal distance in 6 min.Dyspnea was measured using Borg scale before the start of 6MWT and at the end of the test. Portable Spiropalm COSMED recorded heart rate (HR) and oxygen saturation (SpO2) continuously throughout the 6MWT. At the end of the 6MWT, the total covered distance was recorded.

Montreal cognitive assessment test

Time Frame: 1 day

The test, scored on a scale of 0-30 points, is designed to identify cognitive impairment by assessing multiple cognitive domains. MOCA scores between 26 and 30 are consid¬ered normal, while scores \< 26 indicate cognitive impairment

P300 test

Time Frame: 2 days

The electroencephalogram signals were recorded with Fz, Cz, and Pz, electrodes. The P3b and P3a components were identified as the largest positive deflections between 250 ms and 500 ms, respectively, in the target and novel responses. Scalp electrode activity was measured at all electrode sites of which Fz, Cz, and Pz were analyzed. Fz, Cz, and Pz were chosen for analyses because ERPs responses are largest on the midline locations.

Similar Trials